Listed on Nasdaq, NeuBase Therapeutics is a pre-clinical-stage biopharmaceutical company, focusing on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
They’ve recently been recommended as ‘Buy’ and ‘Outperform’ by brokers.